Abstract
Schizophrenia, a complex disease with no current cure, affects about 1% of the US population. The burden of schizophrenia is significantly impacted due to heterogeneity observed across medications’ adherence, efficacy, safety, economic, and effectiveness outcomes. The study goal is to provide an in-depth review of studies that describe the clinical, economic, and humanistic outcomes associated with oral medications in schizophrenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
